Age- and Sex-Related Patterns of First Fracture and Fracture Prevalence
Kara L Holloway, Sharon L Brennan, Mark A Kotowicz, Gosia Bucki-Smith, Amelia G Dobbins, Elizabeth N Timney, Lana J Williams, Julie A Pasco
CALCIFIED TISSUE INTERNATIONAL | SPRINGER | Published : 2015
There are few data documenting the pattern of prevalent fracture across the entire adult age range, so we aimed to address this gap by investigating the prevalence of fractures in an Australian cohort. All-cause (ever) fractures were identified for males and females enrolled in the Geelong Osteoporosis Study (Australia) using a combination of radiology-confirmed and self-reported data. First fractures were used to generate age-related frequencies of individuals who had ever sustained a fracture. Of 1,538 males and 1,731 females, 927 males and 856 females had sustained at least one fracture since birth. The proportion of all prevalent fractures in the 0-10 year age group was similar for both ..View full abstract
Related Projects (2)
Awarded by NHMRC
The study is supported by grants from the Victorian Health Promotion Foundation, National Health and Medical Research Council (NHMRC) of Australia and Amgen (Europe) GmBH. SLB is supported by a NHMRC Early Career Fellowship and LJW is supported by a NHMRC Career Development Fellowship. The study was supported by the National Health and Medical Council (NHMRC), The University of Melbourne Research Grant Scheme, American Society for Bone and Mineral Research (ASBMR), Perpetual Trustees, Amgen and the Geelong Region Medical Research Foundation, but they played no part in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or in preparation, review, or approval of the manuscript. Sharon Brennan was supported by NHMRC Early Career Fellowship (#519404), and NHMRC Postdoctoral (Training) Fellowship (#1012472); Mark Kotowicz was a recipient of the grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation, and Amgen (Europe) GmBH; Julie Pasco was a recipient of grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation, Arthritis Foundation of Australia and Amgen (Europe) GmBH.